

Image

1623



PATENT

Attorney Docket No. 12636-263

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application	)	<u>PATENT APPLICATION</u>
Inventor(s): Joseph Rubinfeld et al.	)	
Application No.: 10/081,974	)	Confirmation No.: 2253
Filed: February 21, 2002	)	Art Unit No.: 1623
Title: Sequential Therapy Comprising A 20(S)- Camptothecin And A Pyrimidine Base Analog	)	Examiner: Fisher, Latonia

Mail Stop IDS  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97**

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☒ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No. 12636-263).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: Nov. 5, 2003

By: 

Shirley Chen, Ph.D., Reg. No. 44,608

650 Page Mill Road  
Palo Alto, CA 94304-1050  
(650) 493-9300  
Customer No. 021971




**CERTIFICATION**

*(Attachment to Information Disclosure Statement)*

- ☒ 37 C.F.R. §1.97(e)(1). **APPLICANT'S UNDERSIGNED ATTORNEY HEREBY CERTIFIES THAT** each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- ☐ 37 C.F.R. §1.97(e)(2). **APPLICANT'S UNDERSIGNED ATTORNEY HEREBY CERTIFIES THAT** no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing this certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.

Respectfully submitted,

Dated: Nov 5, 2003

By:   
Shirley Chen, P.h.D.,  
Reg. No. 44,608

650 Page Mill Road  
Palo Alto, CA 94304-1050  
(650) 565-3856  
Customer No. 021971



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Applicati n No.</b>	10/081,974
				<b>Filing Date</b>	February 21, 2002
				<b>First Named Inventor</b>	Joseph Rubinfeld
				<b>Art Unit</b>	1623
				<b>Examiner Name</b>	Latonia M. Fisher
<b>Sheet</b>	<b>2</b>	<b>Of</b>	<b>2</b>	<b>Attorney Docket No.</b>	12636-263
<b>OTHER PRIOR ART – NON PATENT RELATED DOCUMENTS</b>					
<b>Examiner Initials*</b>	<b>Cite No.<sup>1</sup></b>	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published			<b>T<sup>2</sup></b>
		DEVITA, V., et al., Cancer: Principles and Practice of Oncology, (1997) 5 <sup>th</sup> Edition, pages 335-337.			
		LEE, J.H. et al., Antitumor Activity of 7-[2-(N-Isopropylamino)ethyl]-(20S)-Camptothecin, CKD602, as a Potent DNA Topoisomerase I Inhibitor, <i>Arch Pharm Res.</i> (1998), Vol, 21, No. 5, pages 581-589.			
		LUZZIO, M.J. et al., Synthesis And Antitumor Acitvity of Novel Water Soluble Derivatives of Camptothecin as Specific Inhibitors of Topoisomerase I, <i>Journal of Medicinal Chemistry</i> (1995), Vol. 38, No. 3, pages 395-401.			
		WALL, M.E. et al., Plant Antitumor Agents. 30. <sup>la,b</sup> Synthesis And Structure Activity of Novel Camptothecin Analogs, <i>J Med. Chem</i> (1993) Vol. 36, No. 18, pages 2689-2700.			
<b>EXAMINER SIGNATURE</b>				<b>DATE CONSIDERED</b>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.